Astellas Pharma US Inc.’s third-largest selling drug mirabegron, sold as Myrbetriq extended-release tablets, Betanis and Betmiga by the innovator, is set for competition in the US as Zydus Lifesciences Limited and Lupin Limited prepare for a launch of generic versions of Myrbetriq.
A Myrbetriq Battle Is Brewing And Why It Matters
Lupin To Launch Liraglutide In 2025-26
Zydus and Lupin are gearing up for the US launch of a generic to Astellas Pharma’s blockbuster drug Myrbetriq (mirabegron) while Aurobindo expects a longer wait. Meanwhile, Torrent is preparing to defend its market share in chronic therapies in India as other companies increasingly target this segment
More from Strategy
The Danish drugmaker, best known for dermatology, has secured the European rights to Shanghai Junshi Biosciences’ cancer therapy toripalimab, which was the first Chinese PD-1/L1 checkpoint inhibitor to be approved in the US.
After a less auspicious prelude and a positive start to the biggest healthcare conference of the year, the news flow and investors’ support for biotech initially improved.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
What do industry leaders anticipate as the US installs president Trump once again? Beyond the biopharma sector's biggest market, geopolitical instability has increased elsewhere: how might this affect markets and companies?